Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGAGE: Solriamfetol in Binge Eating Disorder
NCT06413433Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of solriamfetol in binge eating disorder (BED), sponsored by Axsome Therapeutics, Inc.. Started Apr 2024; status: recruiting.
02
Drugs
solriamfetol
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT06413433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413433.